While a large proportion of patients presenting with stage I and II squamous cell carcinoma
of the head and neck (SCCHN) will remain disease free after single modality treatment, the …

Purpose Despite treatment, prognosis of unresectable squamous cell carcinoma of the head
and neck (SCCHC) is dismal. Cetuximab therapy has proven to increase the clinical activity …

Objective To review the available evidence and make recommendations regarding use of
systemically administered drugs in combination or in sequence with radiation (RT) and/or …

Temsirolimus showed clinical efficacy in refractory squamous cell carcinoma of the head
and neck (SCCHN), who failed platinum and epidermal growth factor receptor inhibition …

This paper presents a summary of the evidence review group (ERG) report into the clinical
effectiveness and cost-effectiveness of cetuximab for recurrent and/or metastatic squamous …

Recurrent and metastatic squamous cell carcinoma of the head and neck still carries a poor
prognosis. Response rates with combination chemotherapy regimens are generally higher …

The clinical utility of systemic therapy and genomic profiling in non-squamous-cell head and
neck cancer (NSCHNC) has not been fully elucidated. This phase II trial evaluated the …

Surgery and radiotherapy are generally not an option for recurrent/metastatic head and neck
squamous cell carcinoma. Chemotherapy is the only possible treatment. The five major …

Purpose We hypothesized that the addition of gefitinib, an epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor, to docetaxel would enhance therapeutic efficacy in …

The majority of the head and neck cancers are squamous cell carcinomas, which commonly
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …